Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376155 | 0.89 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL866209 | 0.89 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL1439006 | 0.89 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL4569279 | 0.84 | EPHX2 (0.56) | LMNAALDH1A1EPHX2EPHX1 | |
| SCHEMBL28756703 | 0.82 | EPHX1 (0.41) | LMNAALDH1A1EPHX2EPHX1 | |
| SCHEMBL19504458 | 0.81 | EPHX1 (0.47) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL12404037 | 0.79 | MEN1 (0.50) | LMNAALDH1A1EPHX2SMN1; SMN2MEN1 | |
| SCHEMBL15190565 | 0.79 | LMNA (0.35) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14768741 | 0.78 | EPHX1 (0.63) | ALDH1A1EPHX2SMN1; SMN2EPHX1KMT2A | |
| SCHEMBL19442322 | 0.78 | TEAD1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2024140657-A9 | SUBSTITUTED PHENOL DERIVATIVE AND USE THEREOF | 成都麻沸散医药科技有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| WO-2024140657-A1 | SUBSTITUTED PHENOL DERIVATIVE AND USE THEREOF | 成都麻沸散医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118271237-A | Substituted phenol derivative and use thereof | 成都麻沸散医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| CN-116348116-A | Pyrimidine compound and medical use thereof | 台湾卫生研究院 | 2023-06-27 | — | — | CN | disclosed |
| EP-4079726-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021125803-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-3478680-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-22 | — | — | EP | disclosed |
| CN-105873577-B | Cycloalkenylamides as bromodomain inhibitors | 西奈山伊坎医学院 | 2019-06-18 | — | — | CN | disclosed |
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885ALDH1A1 2776/4885EPHX2 1890/4885 |
| US-10227333-B2 | Inhibition of OLIG2 activity | GLI2, ING2, GMFG | LMNA 4459/4885ALDH1A1 1478/4885EPHX2 294/4885 |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | LMNA 2231/4885ALDH1A1 2226/4885EPHX2 4191/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | LMNA 1852/4885ALDH1A1 1380/4885EPHX2 3226/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | LMNA 2231/4885ALDH1A1 2226/4885EPHX2 4191/4885 |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | LMNA 4804/4885ALDH1A1 939/4885EPHX2 2960/4885 |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | LMNA 4459/4885ALDH1A1 1478/4885EPHX2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.